rs5743836 — TLR9 Promoter -1237T/C

TLR9's Inner Dial — How a Single Promoter Letter Creates an Immune Amplifier

Toll-like receptor 9 (TLR9)¹¹ Toll-like receptor 9 (TLR9)
An endosomal pattern recognition receptor that detects unmethylated CpG dinucleotide motifs in bacterial and viral DNA, triggering innate immune activation through MyD88 and downstream NF-κB and interferon regulatory factor pathways is one of the body's most fundamental alarm systems for microbial invasion. The rs5743836 variant — the third member of the classical TLR9 promoter haplotype trio alongside [rs187084 (-1486T/C) | Located 249 base pairs further upstream of the TLR9 transcription start site; also shows estrogen-responsive regulation and is independently associated with HCV clearance, SLE susceptibility, and osteoarthritis risk] and [rs352140 (exon 2 synonymous) | The most-studied TLR9 variant, altering mRNA stability and TLR9 expression levels without changing the protein sequence] — is positioned 1,237 base pairs upstream of the TLR9 coding sequence in the core promoter region.

In genome files (WGS and consumer chip arrays), this variant is reported as A or G on the plus strand of chromosome 3. Published papers describe it as -1237T/C in coding (minus-strand) notation, because TLR9 lies on the minus strand. The correspondence is: the paper's "T" allele is A on the plus strand (the reference, found in ~79% of people globally), and the paper's "C" allele is G on the plus strand (the alternate at ~21% globally). What makes rs5743836 mechanistically distinct from its companion promoter variant rs187084 is not just its position — it is the nature of the transcription factor binding site it creates.

The Mechanism

The [C allele (plus-strand G) at rs5743836 | Also referred to as -1237C in coding-strand notation throughout the literature] introduces a new regulatory motif at -1237 in the TLR9 promoter: an IL-6-responsive element (IL-6RE)²² IL-6-responsive element (IL-6RE)
A DNA sequence recognized by STAT3, the transcription factor activated downstream of the IL-6 receptor; STAT3 binding to this element drives TLR9 transcription in response to IL-6 signaling. This creates a positive feedback circuit: when TLR9 detects CpG DNA from invading pathogens, it triggers cytokine production including IL-6, which then binds its receptor on immune cells, activates STAT3, and STAT3 binds the newly created IL-6RE to drive further TLR9 transcription. The TT (plus-strand AA) reference genotype lacks this element; the TC (plus-strand AG) and CC (plus-strand GG) genotypes carry it.

[Functional experiments by Carvalho et al. | PLoS One 2011, PMID 22132241] demonstrated this loop directly: TC genotype carriers show higher TLR9 expression when treated with IL-6, and blocking either IL-6 signaling or TLR9 itself reversed the enhanced B-cell proliferation observed in TC individuals upon CpG stimulation. The promoter variant also exhibits [estrogen-responsive regulation | Fischer et al. (Gut 2017, PMID 27196570) showed that both rs5743836 and rs187084 C alleles display estrogen receptor-dependent transcriptional activity, explaining why women carrying these alleles have greater innate immune responses to some pathogens], paralleling the estrogen-dependent effects of the companion rs187084 variant. Together, these features make rs5743836 not merely a quantitative amplifier of TLR9 expression but a qualitative switch that wires TLR9 regulation to two major inflammatory circuits simultaneously: IL-6/STAT3 and estrogen signaling.

The Evidence

The clinical consequences of this molecular wiring are most clearly documented in lymphoma biology, malaria immunity, and sex-specific thrombosis risk.

Non-Hodgkin and Hodgkin lymphoma: The strongest and most replicated association for rs5743836 is with lymphoma. Carvalho et al. (Genes Immun 2012) studied three independent European cohorts totaling over 4,700 subjects: the C allele (plus-strand G) increased NHL risk with OR=1.85 in Portugal (p=7.3×10⁻⁹) and OR=1.84 in Italy (p=6.0×10⁻⁵), though no significant association was seen in the US cohort³³ Carvalho et al. (Genes Immun 2012) studied three independent European cohorts totaling over 4,700 subjects: the C allele (plus-strand G) increased NHL risk with OR=1.85 in Portugal (p=7.3×10⁻⁹) and OR=1.84 in Italy (p=6.0×10⁻⁵), though no significant association was seen in the US cohort
The European-specific replication suggests population-stratified effects, possibly linked to different pathogen exposures and haplotype backgrounds. The mechanistic link is the IL-6/STAT3 pathway: IL-6-driven TLR9 upregulation enhances CpG-induced B-cell proliferation in C allele carriers, and uncontrolled B-cell proliferation is a hallmark of many NHL subtypes. This creates a plausible chain from variant → molecular phenotype → disease.

[A 2022 case-control study in 136 Jordanian Hodgkin lymphoma patients and 238 controls found significantly higher rs5743836 variant allele frequency in cases (p=0.031), with significance across codominant, dominant, and overdominant models | Al-Khatib et al., PLoS One 2022 (PMID 35905120)]. This was synthesized in [a 2025 meta-analysis across multiple cohorts finding OR=1.54 (95% CI 1.03–2.32, p=0.036) in the dominant model for lymphoma overall | Yan et al., BMC Cancer 2025 (PMID 40169945)], confirming the lymphoma association as the most consistent clinical signal for this variant.

Malaria: rs5743836 shows a clear genotype-dose relationship for malaria susceptibility, in the opposite direction from lymphoma. [Omar et al. (Malar J 2012) followed 429 Ghanaian children for one year and found parasitemia levels strongly correlated with rs5743836 genotype: CC (plus-strand GG) carriers had mean parasitemia of 23,532/µL, TC (AG) carriers 14,924/µL, and TT (AA) carriers the lowest at 5,501/µL (p=0.03) | Haplotype analysis showed the TTAG four-SNP haplotype was associated with relative risk of 0.2 for symptomatic malaria (PMID 22594374)]. Independently, [Esposito et al. (Malar J 2012) found CC genotype (plus-strand GG) significantly associated with increased malaria risk in 602 Burundian children (p=0.03) | This was the only TLR9 variant significant for malaria susceptibility in that cohort across 939 subjects (PMID 22691414)].

The paradox — the same allele that drives lymphoma risk also increases malaria susceptibility — resolves when you consider the immunological context. In malaria, the critical host defense is early cytokine-driven clearance of erythrocyte-infected parasites and activation of protective T helper cell responses. Excess IL-6/STAT3-mediated TLR9 upregulation may dysregulate the balance between protective Th1 responses and regulatory immune suppression, paradoxically impairing parasite clearance in the high-IL-6 malaria environment.

Plasmodium vivax vaccine responses: [Carrión-Nessi et al. (PLoS Negl Trop Dis 2025) examined IgG responses against P. vivax circumsporozoite protein (PvCSP) variants in 210 Venezuelan patients. TC (plus-strand AG) heterozygotes produced reduced antibody responses: adjusted OR=0.26 for PvCSP VK247 and OR=0.37 for PvCSP V-like (PMID 40587574)]. High antibody responders had significantly fewer symptoms (p<0.001), implying that genotype-driven antibody differences have clinical consequences for malaria disease burden — and that future P. vivax vaccines may need to account for TLR9 genotype in immunogenicity predictions.

Venous thromboembolism recurrence (sex-specific): [Ahmad et al. (J Thromb Thrombolysis 2017) analyzed 1,050 VTE patients in the Malmö thrombophilia study. In women, rs5743836 was significantly associated with VTE recurrence (HR=3.46, 95% CI 1.06–11.33), rising to HR=5.94 (95% CI 1.25–28.13) for unprovoked VTE. No association was found in men (PMID 28321710)]. The sex specificity aligns with the estrogen-responsive nature of this promoter variant: in women, estrogen-enhanced TLR9 expression may promote thrombo-inflammatory cascades involving platelet TLR9 activation and immune-mediated coagulation dysregulation.

SLE: Despite being a TLR9 promoter variant, rs5743836 does not appear to influence SLE susceptibility. Two large meta-analyses (Wang et al. 2016; Lee & Song 2023; Hu et al. 2017) covering over 5,000 SLE cases found no significant association in any genetic model or ancestry group. The SLE signal in the TLR9 locus appears to be carried primarily by rs187084 in Asian populations, not by rs5743836.

Practical Implications

The G allele's functional impact — creating an IL-6/STAT3 feedback loop in the TLR9 promoter — translates into a heightened and self-amplifying innate immune response when CpG DNA is encountered. The clearest clinical consequences are elevated lymphoma susceptibility (particularly for B-cell lymphomas, where the IL-6-TLR9-B-cell proliferation axis is most directly relevant), increased malaria susceptibility, and female-specific VTE recurrence risk (likely through estrogen-responsive TLR9 amplification of thrombo-inflammatory pathways). There are no established dietary or supplement interventions known to modulate TLR9 promoter activity. The actionable steps for carriers of the G allele center on hematologic vigilance, malaria precautions, and — in women — awareness of the VTE recurrence risk when evaluating anticoagulation decisions.

Interactions

The rs5743836 promoter variant is almost always studied as part of the [TLR9 three-SNP haplotype | The canonical haplotype comprises rs187084 (-1486T/C), rs5743836 (-1237T/C), and rs352140 (exon 2 synonymous) — all three modulate TLR9 expression through different mechanisms and are frequently co-inherited]. The [rs187084 (-1486T/C) | Companion promoter variant 249 base pairs further upstream; shows estrogen-responsive regulation and is significantly associated with SLE in Asians, HCV clearance in women, OA risk, and post-bronchiolitis wheezing] shares the estrogen-responsive regulation with rs5743836, suggesting their combined promoter haplotype may have additive effects on TLR9 expression in women. [Fischer et al. (2017, PMID 27196570) found that both rs187084 and rs5743836 C alleles show estrogen receptor-dependent allele-specific mRNA regulation | The two promoter variants may act synergistically to maximize estrogen-driven TLR9 expression in women]. Individuals carrying C/G alleles at both promoter positions may have the strongest innate immune advantage for viral clearance and the highest liability for TLR9-driven lymphoproliferation.

The pathway context also connects to [TLR4 (rs4986790) | Detects bacterial LPS; a complementary innate immune pathway studied alongside TLR9 in the same Leishmania infantum cohort without significant independent effects] and [TLR2 (rs5743708) | Recognizes bacterial lipoproteins and peptidoglycan; another MyD88-dependent TLR complementary to CpG DNA sensing].